Onlyric 40 Tablet

Onlyric 40 is indicated for long-term treatment of chronic hyperuricemia where urate deposition has already occurred, especially in patients who are intolerant to or inadequately managed by allopurinol. The tablet should be administered orally, with or without food, as directed by a healthcare professional. Dose adjustments may be necessary based on renal function and patient response.

Common adverse effects include liver function abnormalities, nausea, and rash, and patients should be monitored regularly for liver enzyme levels during therapy. Onlyric 40 is contraindicated in patients with hypersensitivity to Febuxostat or in combination with azathioprine or mercaptopurine. It is essential to maintain adequate hydration to prevent renal complications. Consultation with a healthcare provider is recommended before initiating therapy.